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ABSTRACT
Introduction: Oral antidiabetes medications,
including dipeptidyl peptidase-4 inhibitors
(DPP-4is) saxagliptin and sitagliptin, are used
for the treatment of type 2 diabetes (T2D). The
study objective was to compare all-cause and
diabetes-related costs following initiation of
saxagliptin or sitagliptin.
Methods: Patients aged C18 years initiating
saxagliptin or sitagliptin between January 1,
2009 and January 31, 2012 in the Truven Health
MarketScan Commercial and Medicare
Supplemental databases were identified.
Patients were required to have continuous
enrollment for C365 days before and
C365 days after the index date (date of the
first saxagliptin or sitagliptin claim).
Additionally, patients were required to have a
claim with a T2D diagnosis (ICD-9-CM 250.90,
250.92) and no claims for a DPP-4i medication
before the index date. All-cause and
diabetes-related medical costs and total costs
(including pharmacy costs) were captured over
the 1-year follow-up period. Generalized linear
models with log link and gamma distribution
were fit to compare costs between the two
cohorts using cost ratios, controlling for patient
baseline characteristics. Recycled prediction
methods were used to generate adjusted
predicted costs and confidence intervals.
Results: The final sample comprised 3354
saxagliptin initiators and 26,895 sitagliptin
initiators. The average age of saxagliptin and
sitagliptin initiators was 57 years and just over
50% were males. After adjusting for baseline
characteristics, saxagliptin patients had
significantly lower average all-cause medical
costs (cost ratio = 0.901, P\0.001; predicted
mean costs: $8687 vs. $9646) compared with
sitagliptin patients over the 1-year follow-up.
Findings were consistent for diabetes-related
medical costs (cost ratio = 0.890, P\0.001;
predicted mean costs: $2180 vs. $2450). Total
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costs were also lower for saxagliptin initiators
(cost ratio = 0.950, P = 0.002; predicted mean
costs: $13,911 vs. $14,651) over the 1-year
follow-up period.
Conclusion: Initiation of treatment with
saxagliptin was associated with lower medical
costs over 1 year compared with initiation of
sitagliptin among adults with T2D.
Funding: AstraZeneca.
Keywords: Dipeptidyl peptidase-4 inhibitors;
Healthcare costs; Saxagliptin; Sitagliptin; Type
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INTRODUCTION
The American Diabetes Association reports that
between 2007 and 2012, the total cost of
diabetes in the United States increased 41%
from $174 billion (2007 USD) to $245 billion
(2012 USD) [1]. Direct medical costs accounted
for $176 billion [1]. The primary components of
the costs were direct medical costs for
inpatient care, prescription medications to
treat diabetes-related complications, and
antidiabetes therapies and supplies,
responsible for 43%, 18%, and 12% of the
$176 billion sum, respectively [1]. An
additional $69 billion was attributed to lost
productivity [1]. Compared with individuals
without diabetes, patients diagnosed with
diabetes have 2.3 times greater healthcare
costs, averaging $13,741 annually compared
with $5853 [1]. Therefore, an estimated $7888
in excess costs per year per person may be
associated with diabetes [1].
For patients with type 2 diabetes (T2D), the
primary goal of treatment is to achieve and
maintain glycemic control [2], as poor glycemic
control is associated with numerous
microvascular and macrovascular complications
including, but not limited to, diabetic
nephropathy, retinopathy, coronary artery
disease, and stroke [3]. For patients with T2D,
standards of care recommend metformin first for
appropriate patients in combination with dietary
and lifestyle modifications, and if treatment
failure occurs, the addition of a supplementary
non-insulin agent such as a glucagon-like
peptide-1 receptor agonist (GLP-1 RA), sodium
glucose cotransporter 2 inhibitor (SGLT-2i),
dipeptidyl peptidase-4 inhibitor (DPP-4i),
thiazolidinedione (TZD), sulfonylurea (SU), or
meglitinide (GLN) [2–4].
In the United States, two commonly used
DPP-4i medications are saxagliptin and
sitagliptin. Compared with patients who
initiated sitagliptin, saxagliptin initiators have
been found to have better medication
adherence and persistence [5]. Additionally,
saxagliptin initiators were reported to have
lower all-cause and diabetes-related medical
costs over the 6 months following initiation
[6]. Direct cost comparisons between patients
treated with one of these two DPP-4i
medications over longer periods of time are
not available. This retrospective claims-based
study sought to add to the body of available
evidence by comparing the healthcare
utilization and costs among patients with T2D
who initiated saxagliptin to those who initiated




This retrospective observational cohort study
used administrative claims data to analyze the
all-cause and diabetes-related healthcare
resource utilization and costs for patients with
T2D who initiated saxagliptin or sitagliptin
between January 1, 2009, and January 31,
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2012. The patients included in this analysis
were a subset of a previously identified sample
of patients with T2D [5]. Among these patients,
healthcare resource utilization and costs were
compared among saxagliptin initiators and
sitagliptin initiators over the 12 months
following DPP-4i initiation.
Data Sources
Two Truven Health MarketScan research
databases were used in this study: the
Commercial Claims and Encounters Database
(Commercial) and the Medicare Supplemental
and Coordination of Benefits Database
(Medicare Supplemental). The Commercial
database contains the inpatient and outpatient
medical and outpatient prescription drug
experience of several million lives annually.
The Medicare Supplemental database contains
the healthcare experience (both medical and
pharmacy) of individuals with Medicare
supplemental insurance paid for by employers.
Both databases provide detailed cost, use, and
outcomes data for healthcare services
performed in both inpatient and outpatient
settings across a variety of fee-for-service, fully
capitated, and partially capitated health plans.
The health plans include preferred provider
organizations, point of service plans,
indemnity plans, and health maintenance
organizations. The medical claims are linked
to outpatient prescription drug claims and
person-level enrollment data through the use
of unique enrollee identifiers.
Inclusion Criteria
The Commercial and Medicare Supplemental
databases were used to identify adults (age
C18 years) with at least one prescription for
saxagliptin or sitagliptin during the period
extending from January 1, 2009 to January 31,
2012. The service date on the first observed
prescription for saxagliptin or sitagliptin was
defined as the index date and the drug filled on
the index date was designated the index drug.
Patients were required to have at least 28 days of
continuous days supplied of the index drug to
qualify for the study. Additionally, patients
were required to have continuous medical and
pharmacy benefits enrollment for at least
12 months prior to and following the index
date. Patients were required to have a medical
claim with a diagnosis of T2D (International
Classification of Diseases, Ninth Edition,
Clinical Modification [ICD-9-CM] code 250.90
or 250.92); however, patients were excluded if
they had a prescription for a DPP4-i medication
in the year prior to index or a diagnosis of type 1
diabetes mellitus (ICD-9-CM code 250.91 or
250.93) or gestational diabetes (ICD-9-CM code
648.89) on a medical claim at any time during
the study period. Patients were allowed to have
prescription claims for other antidiabetes
medications prior to the index date. These
patient selection criteria have been published
previously [5]. Patients were stratified into two
cohorts based on index drug: saxagliptin
initiators or sitagliptin initiators. This was an
intent-to-treat analysis.
Outcomes
Healthcare utilization and costs were measured
during the 12 months following the index date
(follow-up period). Both all-cause and
diabetes-related resource utilization and costs
were captured. Diabetes-related measures were
defined as medical claims with a primary or
non-primary diagnosis of T2D (ICD-9-CM
250.90, 250.92) or an outpatient claim for an
antidiabetes medication. The following service
categories were captured: inpatient admissions,
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emergency room (ER) visits, outpatient
physician office visits, other outpatient
services (including laboratory and radiology
services, ambulatory care, dialysis, etc.), which
were all considered medical costs, and
outpatient pharmacy fills. Pharmacy fills for
index drug (saxagliptin or sitagliptin) were also
captured. Costs were the paid amount on
claims, including insurer- and patient-paid
portions. Medical, pharmacy, and total costs
(the sum of medical and pharmacy costs) were
adjusted to 2013 US dollars using the medical
care component of the Consumer Price Index
[7], as the 12 months of follow-up extended
into 2013 for some patients. Costs for capitated
claims were imputed using a payment proxy
based on the payment of non-capitated claims
with the same procedure code in the same year,
from the region. The primary outcomes of
interest were all-cause and diabetes-related
medical costs, all-cause and diabetes-related
pharmacy costs, and total all-cause and
diabetes-related healthcare costs. Secondary
outcomes were presence of all-cause and
diabetes-related inpatient admissions and
inpatient costs, all-cause and diabetes-related
other outpatient medical costs, and index drug
(saxagliptin or sitagliptin) pharmacy costs, as
these were the main drivers of costs in this
population.
As adherence and persistence to medications
may be associated with higher diabetes-related
pharmacy costs and lower diabetes-related
medical costs, adherence to and persistence
with saxagliptin and sitagliptin over the
12-month follow-up period was also measured.
Proportion of days covered (PDC) was used to
measure adherence. PDC was calculated by
dividing the number of days the patient was
covered on index drug during the 12-month
follow-up period by 365 days. If there was an
overlap in index drug, the overlapping days
supply was appended to the previous
prescription’s end. Patients with PDC C0.80
were considered adherent. Discontinuation of
the initiated drug was also evaluated. Patients
were followed starting with their index
prescription and were considered to have
‘discontinued’ if they had a gap of more than
60 days without any drug supply available
during the 12-month follow-up.
Covariates
Patient demographics and baseline
characteristics were captured. Demographic
characteristics were measured at index date
and included age, gender, geographic region,
insurance plan type, and index year. Use of
other antidiabetes medications, including
insulin, was captured during the 12 months
prior to the index date based on pharmacy
claims. Comorbid conditions based on
diagnosis and procedure codes on medical
claims, and healthcare costs were also
measured during this period. Index drug was
classified as mail order or non-mail order. Cost
sharing for the index drug, defined as the
average patient out-of-pocket cost for a 30-day
supply on index drug for patients in each
insurance plan, was also calculated [8]. Lastly,
claims for non-DPP-4i antidiabetes medications
filled around the time of the index date were
evaluated to determine if a patient was using
any other classes of antidiabetes medications in
combination with saxagliptin or sitagliptin.
Based on these claims, a patient’s ‘index
regimen’ was determined and classified as
polytherapy or monotherapy. Patients were
considered to be on polytherapy if they had
(A) one pharmacy claim in the 60 days prior to
the index date and a second pharmacy claim in
the 45 days following index for a non-DPP-4i
drug; (B) had a pharmacy claim for a
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non-DPP-4i drug during the time window index
date -60 days to index date ?45 days that
overlapped with index drug for at least 30 days
in the first 45 days following index date; or
(C) indexed on a fixed-dose metformin
combination drug [5]. All other patients were
considered to be on a monotherapy regimen [5].
A full list of study covariates is included in
Table 1.
Statistical Analyses
Demographic, clinical, treatment regimen
characteristics, and outcomes (Tables 1, 2, 3)
were compared between the saxagliptin and
sitagliptin cohorts using t tests for continuous
variables and Chi-squared tests for categorical
variables. Multivariable generalized linear
models (GLMs) with a log link and gamma
error distribution were used to compare costs
among patients initiating saxagliptin and
sitagliptin. A log link and gamma error
distribution were used to handle the
non-normal cost distributions. If the P value
for the cost ratio of the cohort coefficient from
the model was \0.05, the difference between
the saxagliptin and sitagliptin cohorts was
considered statistically significant. To present
adjusted costs on the dollar scale, the recycled
prediction method was used to generate
predicted mean costs. In the recycled
prediction method, mean costs are calculated
for two pseudo-samples (one saxagliptin and
one sitagliptin), the size of both pseudo-samples
being the total number of patients. Each
pseudo-sample is a combination of observed
values for those patients who had the treatment
concerned and predicted counterfactuals for
those patients who had the other treatment.
Although the same methods of GLMs with
log link and gamma error distribution, followed
by use of the recycled prediction method to
calculate adjusted costs on the dollar scale, were
used to analyze all cost variables in separate
models, the actual process followed was
different for the inpatient cost variables and
the others, i.e., total, medical, other outpatient
medical and pharmacy costs. The reason for this
difference is that a high percentage
(approximately 90%) of inpatient costs were
zero, i.e., the patient had no such costs, whereas
for the other cost variables, hardly any patients
had zero costs.
Therefore, for the inpatient costs only, a
two-part modeling approach was used to
estimate predicted probability of all-cause and
diabetes-related inpatient admission and
inpatient costs to account for patients with $0.
First, logistic regression models were fit to model
the odds of inpatient admission and the estimates
of coefficients from these models were used to
generate predicted probabilities of inpatient
admission. Second, GLMs with log link and
gamma error distribution were fit to obtain
predicted inpatient costs among patients with
non-zero costs. To obtain average inpatient costs
for each cohort, the predicted probability of
inpatient admission was multiplied by the
predicted costs. Bootstrapping, using 1000
resamples of the observed data, was used to
generate 95% confidence intervals around
probability of inpatient admission and average
inpatient costs, these estimates of intervals and
averages being taken from the bootstrapping
distributions of the 1000 resamples.
For total, medical, other outpatient medical
and pharmacy costs, only the GLMs with log
link and gamma error distribution were fit
(essentially discarding patients with zero
costs), and bootstrapping was not used. The
recycled prediction estimate of cost on the
dollar scale for these outcomes was from the
single analysis of the observed data. For these
costs, the estimates of averages and 95%
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N5 30,249 N5 3354 N5 26,895
Age (mean, SD) 56.8 11.7 57.0 11.5 56.8 11.7 0.253
Male (N, %) 15,244 50.4% 1697 50.6% 13,547 50.4% 0.805
Geographic region (N, %)
Northeast 4978 16.5% 520 15.5% 4458 16.6% \0.001
North Central 7296 24.1% 766 22.8% 6530 24.3%
South 13,444 44.4% 1700 50.7% 11,744 43.7%
West 4286 14.2% 360 10.7% 3926 14.6%
Unknown 245 0.8% 8 0.2% 237 0.9%
Population density (N, %)
Metro 25,270 83.5% 2780 82.9% 22,490 83.6% \0.001
Non-metro 4746 15.67% 566 16.9% 4180 15.5%
Unknown 233 0.8% 8 0.2% 225 0.8%
Presence of capitated services (N, %) 2405 8.0% 143 4.3% 2262 8.4% \0.001
Primary payer (N, %)
Commercial 23,538 77.8% 2606 77.7% 20,932 77.8% 0.864
Medicare 6711 22.2% 748 22.3% 5963 22.2%
Plan type (N, %)
Comprehensive 4148 13.7% 548 16.3% 3600 13.4% \0.001
EPO 276 0.9% 42 1.3% 234 0.9%
HMO 4427 14.6% 348 10.4% 4079 15.2%
POS 2968 9.8% 389 11.6% 2579 9.6%
PPO 15,587 51.5% 1661 49.5% 13,926 51.8%
POS with capitation 120 0.4% 8 0.2% 112 0.4%
CDHP/HDHP 1171 3.9% 136 4.1% 1035 3.8%
Unknown 1552 5.1% 222 6.6% 1330 4.9%
Index year (N, %)
2009 16,001 52.9% 359 10.7% 15,642 58.2% \0.001
2010 13,656 45.1% 2823 84.2% 10,833 40.3%
2011 592 2.0% 172 5.1% 420 1.6%
Unique number 3-digit ICD-9-CM diagnosis
codes in baseline period (mean, SD)
10.3 7.6 10.6 7.7 10.2 7.6 0.020
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confidence intervals for costs on the dollar scale
were from the distributions of the two
pseudo-samples.
All aforementioned models controlled the
following variables: age, sex, presence of
capitated services, payer, region, population
density (metro vs. non-metro), plan type, index
year, indicator for fixed-dose metformin index
drug, indicator for index drug filled via mail
order, index regimen (monotherapy, index drug
plus additional non-insulin antidiabetic drugs
[NIAD], index drug plus insulin), baseline total
healthcare costs and diabetes prescription









N5 30,249 N5 3354 N5 26,895
Deyo CCI in baseline period (mean, SD) 1.6 1.3 1.6 1.3 1.6 1.3 0.416
Renal impairment in baseline period (N, %) 1958 6.5% 227 6.8% 1731 6.4% 0.461
Microvascular disease in baseline period (N, %) 3838 12.7% 416 12.4% 3422 12.7% 0.599
Macrovascular disease in baseline period (N, %) 6430 21.3% 724 21.6% 5706 21.2% 0.621
Pregnancy in follow-up period (N, %) 60 0.2% 5 0.1% 55 0.2% 0.496
Metformin in baseline period (N, %) 18,366 60.7% 2220 66.2% 16,146 60.0% \0.001
Insulin in baseline period (N, %) 2289 7.6% 246 7.3% 2043 7.6% 0.589
Endocrinologist visit in baseline period (N, %) 3020 10.0% 324 9.7% 2696 10.0% 0.507
Cardiologist visit in baseline period (N, %) 7634 25.2% 835 24.9% 6799 25.3% 0.629
Total healthcare costs in baseline period
(mean, SD)
$11,984 $27,932 $11,341 $19,626 $12,064 $28,800 0.158
Diabetes medication costs in baseline period
(mean, SD)
$376 $927 $374 $969 $377 $922 0.897
Index prescription part of ﬁxed-dose
combination with metformin (N, %)
10,174 33.6% 36 1.1% 10,138 37.7% \0.001
Mail-order index study class prescription (N, %) 6716 22.2% 645 19.2% 6071 22.6% \0.001
Index drug cost-sharing index (mean, SD) $24 $14 $26 $13 $24 $14 \0.001
Index drug regimen category (N, %)
Monotherapy 9432 31.2% 1539 45.9% 7893 29.3% \0.001
DPP-4i plus 1 other NIAD 17,648 58.3% 1561 46.5% 16,087 59.8%
DPP-4i plus 2? other NIAD 1457 4.8% 86 2.6% 1371 5.1%
DPP-4i plus insulin 643 2.1% 90 2.7% 553 2.1%
DPP-4i plus insulin and other NIAD 1069 3.5% 78 2.3% 991 3.7%
CCI Charlson Comorbidity Index, CDHP Consumer-directed health plan, DPP-4i dipeptidyl peptidase-4 inhibitor, EPO
exclusive provider organization, HDHP high-deductible health plan, HMO health maintenance organization, NIAD
non-insulin antidiabetes drug, POS point of service, PPO preferred provider organization, SD standard deviation
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N5 30,249 N5 3354 N5 26,895
All-cause
Inpatient admissions
Patients with an inpatient admission (N, %) 3727 12.3% 372 11.1% 3355 12.5% 0.022
Inpatient admission costs (mean, SD) $3034 $16,511 $2976 $15,421 $3042 $16,642 0.829
ER visits
Patients with an ER visit (N, %) 6558 21.7% 745 22.2% 5813 21.6% 0.428
ER visit costs (mean, SD) $250 $1073 $237 $851 $252 $1098 0.444
Outpatient ofﬁce visits
Patients with an outpatient ofﬁce visit (N, %) 29,726 98.3% 3311 98.7% 26,415 98.2% 0.035
Outpatient ofﬁce visit costs (mean, SD) $857 $748 $839 $685 $859 $756 0.145
Other outpatient services
Patients with other outpatient services (N, %) 29,674 98.1% 3289 98.1% 26,385 98.1% 0.867
Other outpatient services costs (mean, SD) $5471 $18,541 $5162 $12,603 $5510 $19,152 0.306
Total all-cause medical costs (mean, SD) $9613 $27,513 $9215 $22,075 $9663 $28,117 0.374
Outpatient pharmacy prescriptions
Patients with an outpatient pharmacy
prescription (N, %)
30,249 100.0% 3354 100.0% 26,895 100.0%
Outpatient pharmacy prescription costs
(mean, SD)
$5228 $5245 $5626 $6064 $5178 $5131 \0.001
Total all-cause healthcare costs (mean, SD) $14,841 $28,758 $14,841 $24,012 $14,841 $29,296 1.000
Diabetes-relateda
Inpatient admissions
Patients with a diabetes-related inpatient
admission (N, %)
2194 7.3% 225 6.7% 1969 7.3% 0.197
Diabetes-related inpatient admission costs
(mean, SD)
$1014 $9625 $998 $8231 $1016 $9785 0.917
ER visits
Patients with a diabetes-related ER visit (N, %) 2289 7.6% 250 7.5% 2039 7.6% 0.792
Diabetes-related ER visit costs (mean, SD) $72 $557 $67 $460 $72 $568 0.608
Outpatient ofﬁce visits
Patients with a diabetes-related outpatient ofﬁce
visit (N, %)
26,342 87.1% 2923 87.1% 23,419 87.1% 0.904
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cost sharing, baseline endocrinologist and
cardiologist visits, baseline renal impairment,
baseline macrovascular and microvascular
disease, pregnancy during follow-up, baseline
number of unique 3-digit ICD-9 diagnoses and
Deyo Charlson Comorbidity Index [9]. Variables
included were hypothesized to be potential
confounders of the relationship between the
type of drug initiated and post-initiation costs,
as this was an observational analysis and patients
were not randomly assigned to receive
saxagliptin or sitagliptin. The covariates listed
above are demographic characteristics and
clinical characteristics, including proxies for
severity of diabetes, which may affect a
clinician’s choice of medication and may also
affect costs. Analyses were conducted using SAS
version 9.3 (SAS Institute Inc., SAS Campus
Drive, Cary, NC, USA).
Compliance with Ethic Guidelines
The analyses presented are based on previously
collected, de-identified data, and do not contain
any new studies with human subjects









N5 30,249 N5 3354 N5 26,895
Diabetes-related outpatient ofﬁce visit costs
(mean, SD)
$288 $272 $279 $260 $290 $273 0.035
Other outpatient services
Patients with a diabetes-related other outpatient
services (N, %)
26,455 87.5% 2949 87.9% 23,506 87.4% 0.386
Diabetes-related other outpatient services costs
(mean, SD)
$959 $11,810 $741 $2185 $986 $12,501 0.276
Total diabetes-related medical costs (mean, SD) $2333 $15,555 $2085 $8725 $2364 $16,205 0.327
Outpatient pharmacy prescriptions
Patients with a diabetes-related outpatient
pharmacy prescriptions (N, %)
30,249 100.0% 3354 100.0% 26,895 100.0%
Diabetes-related outpatient pharmacy
prescriptions costs (mean, SD)
$2155 $1439 $2285 $1423 $2138 $1440 \0.001
Number of outpatient pharmacy prescriptions
for saxagliptin/sitagliptin (mean, SD)
– – 6.1 3.7 5.7 3.5 \0.001
Outpatient pharmacy prescriptions costs for
saxagliptin/sitagliptin (mean, SD)
– – $1756 $912 $1661 $925 \0.001
Total diabetes-related healthcare costs
(mean, SD)
$4488 $15,639 $4370 $8857 $4503 $16,288 0.643
DPP-4i dipeptidyl peptidase-4 inhibitor, ER emergency room, SD standard deviation
a Diabetes-related measures were deﬁned as medical claims with a primary or non-primary diagnosis of type 2 diabetes
mellitus (ICD-9-CM 250.90, 250.92) in any position or an outpatient claim for an antidiabetes medication
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RESULTS
Patient Demographics
There were 30,249 DPP-4i initiators who met the
study criteria and among them, 3354 initiated
saxagliptin (11.1%). Demographic characteristics
are presented in Table 1. On average, patients
were approximately 57 years old and slightly
more than half were male, with no significant
differences between saxagliptin and sitagliptin
initiators. A significantly larger proportion of
saxagliptin initiators resided in the South. The
majority of patients insured through a
commercial plan (approximately 78%) and a
significantly smaller proportion of saxagliptin
initiators had evidence of capitated services.
Clinical Characteristics and Index
Regimen Characteristics
Clinical characteristics and index regimen
characteristics are also presented in Table 1.
During the baseline period, 6.5%, 12.7%, and
21.3% of study patients had evidence of renal
impairment, microvascular disease (as
evidenced by diabetic peripheral neuropathy,
diabetic retinopathy, leg and foot amputation,
or nephropathy), and macrovascular disease
(characterized by evidence of acute myocardial
infarction, other ischemic heart disease,
congestive heart failure, cerebrovascular
accident, or peripheral vascular disease),
respectively, with no significant differences
between the two cohorts. Overall, however,
saxagliptin patients had a significantly greater
number of unique ICD-9-CM diagnosis codes
prior to the index date. A significantly larger
proportion of saxagliptin initiators used
metformin during the baseline period. There
were no significant differences in total
healthcare costs or diabetes medication costs
during the baseline period, although total
healthcare costs tended to be lower for
saxagliptin initiators, on average. Regarding
index regimen, a significantly smaller
proportion of saxagliptin initiators had an
index prescription that was a fixed-dose
Table 3 Adherence and persistence to initiated DPP-4i over 12-month follow-up
DPP-4i initiators Saxagliptin initiators Sitagliptin initiators P value
N5 30,249 N5 3354 N5 26,895
Adherence
PDC
Mean, SD 0.67 0.32 0.67 0.32 0.66 0.32 0.016
Median 0.77 0.81 0.75
Adherent patients (N, %) 14,571 48.2% 1699 50.7% 12,741 47.4% \0.001
Persistence
Days persistent
Mean, SD 253.15 136.41 258.77 134.64 250.98 136.85 0.002
Median 365 365 365
Discontinued (N, %) 13,377 44.2% 1423 42.4% 12,120 45.1% 0.004
DPP-4i dipeptidyl peptidase-4 inhibitor, PDC proportion of days covered, SD standard deviation
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combination with metformin. Initiating
monotherapy was significantly more common
among saxagliptin initiators.
Healthcare Resource Utilization and Costs
Saxagliptin initiators tended to have lower
unadjusted all-cause and diabetes-related
medical costs than sitagliptin initiators in all
service categories but most of the cost
comparisons were not statistically significant
(Table 2). Average outpatient pharmacy
prescription costs were significantly higher for
saxagliptin initiators. Healthcare utilization was
similar between the two cohorts, although the
proportion of patients with an all-cause
inpatient admission was significantly smaller
in the saxagliptin cohort.
Results from multivariable models
controlling for covariates and predicted costs
are presented in Fig. 1. Over the 12 months
following initiation, saxagliptin patients had
9.9% lower all-cause medical costs and 11.0%
lower diabetes-related medical costs than
patients who initiated sitagliptin. Differences
in predicted mean all-cause medical and
diabetes-related medical costs between the two
cohorts were $959 and $270, respectively,
favoring saxagliptin. Additionally, all-cause
and diabetes-related total costs were both
approximately 5.0% lower in saxagliptin
patients. Pharmacy costs, however, were
higher among saxagliptin initiators with a
difference in predicted mean all-cause costs of
$207, and difference in predicted mean
diabetes-related cost of $51. When evaluating
saxagliptin and sitagliptin prescription costs for
the two cohorts, the saxagliptin cohort tended
to have higher costs but the difference was not
statistically significant. Results for inpatient
 
 Adjusted saxagliptin  
costs (95% CI) 
Adjusted sitagliptin  
costs (95% CI) 
Saxagliptin vs. sitagliptin 
adjusted cost ratio 
(95% CI) 
P value 
for cost  
ratio 
All-cause medical costs $8687 ($8604–8769) $9646 ($9555–9737) 0.901 (0.858–0.945) <0.001 
Diabetes-related medical costs $2180 ($2162–2198) $2450 ($2430–2470) 0.890 (0.842–0.941) <0.001 
All-cause pharmacy costs $5400 ($5376–5424) $5193 ($5170–5216) 1.040 (1.014–1.066) 0.002 
Diabetes-related pharmacy costs $2218 ($2210–2227) $2167 ($2158–2175) 1.024 (1.000–1.049) 0.053 
Saxagliptin/sitagliptin pharmacy costs $1710 ($1707–1713) $1689 ($1686–1692) 1.013 (0.987–1.039) 0.347 
All-cause total costs $13,911 ($13,816–14,007) $14,651 ($14,551–14,752) 0.950 (0.919–0.981) 0.002 
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Fig. 1 All-cause and diabetes-related medical, pharmacy, and total costs over 12-month follow-up period. Asterisk a
statistically signiﬁcant difference (P\0.05) between saxagliptin initiators and sitagliptin initiators. CI conﬁdence interval
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admission and costs are presented in Table S1 in
the supplementary material. The predicted
proportion of saxagliptin patients with an
inpatient admission (11.0%) was significantly
smaller than the predicted proportion of
sitagliptin patients (12.5%, difference = 1.5%,
95% confidence interval -2.5%, -0.2%). There
were no significant differences in predicted
proportion of patients with a diabetes-related
inpatient admission or predicted inpatients
costs. Results for other outpatient medical
costs models are presented in Table S2 in the
supplementary material. Compared with
sitagliptin patients, saxagliptin patients had
significantly lower predicted all-cause other
outpatient medical costs ($4834 vs. $5457)
and predicted diabetes-related outpatient
medical costs ($848 vs. $1093).
Adherence and Persistence to Initiated
Medication during Follow-Up
As shown in Table 3, over the 12-month
follow-up period, the proportion of patients
who were adherent was significantly greater in
the saxagliptin cohort compared with the
sitagliptin cohort in an unadjusted analysis.
Similarly, a smaller proportion of saxagliptin
initiators discontinued index drug during
follow-up. The average number of index drug
prescription fills was significantly higher for the
saxagliptin cohort compared with the
sitagliptin cohort (Table 2).
DISCUSSION
In this retrospective, observational claims-based
analysis of adults with T2D, all-cause and
diabetes-related medical costs were lower
among saxagliptin initiators compared with
sitagliptin initiators over a 12-month
follow-up period. Additionally, total all-cause
and diabetes-related healthcare costs were also
lower in saxagliptin patients, although the
magnitudes of the differences were smaller due
to the tendency of saxagliptin patients to have
greater pharmacy costs. Presently, there is very
little information available directly comparing
real-world costs and healthcare resource
utilization among saxagliptin and sitagliptin
initiators. To our knowledge, this is the first
analysis to compare costs and utilizations
among patients initiating one of the DPP-4i
medications over a 12-month follow-up period.
Potential explanations for lower costs
observed in saxagliptin patients in this study
include a lower proportion of patients with
inpatient admissions among saxagliptin
initiators (11.1% saxagliptin vs. 12.5%
sitagliptin) as well as better adherence and
persistence to the index drug among saxagliptin
initiators. Saxagliptin patients were more
adherent over the 12-month follow-up (50.7%
saxagliptin vs. 47.4% sitagliptin) and had
decreased odds of all-cause inpatient admission.
Previous research has found that within the
DPP-4i medication class, patients initiating
saxagliptin had better adherence and
persistence than patients who initiated
sitagliptin [5]. Increasing adherence to
antidiabetes medication has been correlated
with increased glycemic control and decreased
healthcare costs and resource utilization [10–12].
A previous investigation by Kaltenboeck
et al. [6] evaluated healthcare costs and
utilization over 6 months following the
initiation of saxagliptin, sitagliptin, or SU.
Only unadjusted utilization results were
presented [6]. Over the short follow-up period,
significantly smaller proportions of saxagliptin
initiators had an all-cause inpatient admission
or an ER visit compared with sitagliptin
initiators (7.2% vs. 10.6% and 14.1% vs.
17.5%, respectively) [6]. The same was true for
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diabetes-related inpatient admissions (4.0% vs.
6.6%) and diabetes-related ER visits (5.7% vs.
7.3%) [6]. The saxagliptin cohort had a
significantly greater proportion of patients
with a diabetes-related outpatient visit (80.2%
vs. 78.6%) [6]. Unadjusted mean all-cause and
diabetes-related total costs were significantly
lower for saxagliptin initiators than sitagliptin
initiators ($7346 vs. $8797 and $2445 vs. $2828,
respectively) [6]. Mean costs were significantly
lower for all service categories except
diabetes-related outpatient visits and
diabetes-related prescription costs, although
saxagliptin initiators tended to have lower
costs for both [6]. The findings after adjusting
for patient demographic and clinical
characteristics were consistent [6]. Saxagliptin
patients had significantly lower all-cause
medical ($5073 vs. $5535, P\0.001) and total
costs ($7802 vs. $8302, P\0.001) [6].
Additionally, compared with sitagliptin
patients, saxagliptin patients had significantly
lower diabetes-related medical ($1149 vs.
$1387, P\0.001) and total costs ($2510 vs.
$2772, P\0.001) [6].
This study has several limitations to
acknowledge. First, administrative claims data
are not collected for research purposes, as the
diagnostic coding on administrative claims is
recorded by physicians to support
reimbursement. Diagnoses on claims may be
coded incorrectly, or not at all, thereby
potentially introducing measurement error
with respect to variables that incorporated
ICD-9-CM codes into their definitions.
Similarly, prescriptions that were filled and did
not generate an insurance claim were not
captured in this analysis. Adherence and
persistence were calculated using the service
date and days supply information found on
outpatient prescription drug claims and while it
is assumed that the medication was taken as
directed, skipped doses or discontinuation of
the medication before the end of the current
days supply could not be captured. Next,
observational analyses may be subject to
residual confounding even after multivariable
adjustment, and causal inferences should be
made cautiously. Lastly, study findings may not
be generalizable to the entire Medicare
population, Medicaid population, or uninsured
population as the MarketScan Commercial and
Medicare Supplemental databases contain data
only on patients receiving coverage through
employers, private commercial insurance, or
employer-sponsored supplemental Medicare.
CONCLUSIONS
For adults with T2D, initiation of treatment
with saxagliptin was associated with lower
all-cause and diabetes-related medical costs
over 1 year compared with sitagliptin. The
differences in costs may be due in part to
better adherence and fewer hospitalizations
among saxagliptin initiators.
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